Catriona Yale - Jun 30, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 30, 2025
Transactions value $
$21,243
Form type
4
Date filed
7/2/2025, 06:00 PM
Previous filing
Jun 20, 2025
Next filing
Jul 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yale Catriona Chief Development Officer 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young, Attorney-in-Fact 2025-07-02 0001779308

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $21.2K +890 +0.98% $23.87 91.5K Jun 30, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Yale is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025.